Investigating the effect of oral and topical Cicaglocal drug on wound healing
Phase 1
Recruiting
- Conditions
- lcer.Other and unspecified malignant neoplasm of skin
- Registration Number
- IRCT20220306054206N3
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Patients who have undergone Mohs surgery due to skin cancer of the head and face
Age should be in the range of 50 to 80 years.
Completing the consent form to participate in the study
Exclusion Criteria
Surgery in an area of ??the body other than the head and face
Skin cancer of a type other than SCC and BCC
The presence of a specific underlying disease that directly leads to a disorder in wound healing, including scleroderma and morphea
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determining the effect of oral and topical cikaglocal drug on wound healing in patients after Mohs surgery, where the wound healing score is given based on the Early Healing Index (EHI). Timepoint: In each group, the number of patients will be 12, and on days 0, 7, and 14, imaging of the patients' wounds will be done, and the duration of drug use is 14 days. Method of measurement: The wound healing score is based on the Early Healing Index (EHI), which evaluates wound healing using scores from 1 to 5: a wound with very poor healing receives a score of 1, while excellent healing receives a score of 5. slow.
- Secondary Outcome Measures
Name Time Method